BioPharmSignal logoBioPharmSignal

Biotech News

Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

Barinthus Biotherapeutics (BRNS)Barinthus BiotherapeuticsEarnings

The final cohort of the single ascending dose (SAD) part of the Phase 1 A VALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025; The multiple ascending dose (MAD) part of the AVALON trial initiated; Available resources and cash runway guidance into 2027

Open original release

Related news

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

FATEFate Therapeutics2026-05-13 12:30 EST

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

ERASErasca2026-05-11 20:01 EST

Erasca Reports First Quarter 2026 Business Updates and Financial Results

GNLXGenelux2026-05-07 20:15 EST

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

ARGXArgenx2026-07-16 05:00 EST

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

ARGXArgenx2026-07-23 05:00 EST

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

View all latest news

Barinthus Biotherapeutics

Barinthus Biotherapeutics is an immunotherapy company focused on vaccines and T-cell therapies for infectious disease and oncology. Its story is built around immune-based approaches to both prevention and treatment.

Recent company news

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2026-03-13 12:00 EST

Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2025-12-10 13:00 EST

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

BRNSBarinthus Biotherapeutics2025-11-07 12:30 EST

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2025-09-30 12:01 EST

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

Stock data

Close
0.57 USD
Market cap
26.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States